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Abstract
Background: Anxiety and depressive disorders are common mental disorders. A substantial part of patients does
not achieve symptomatic remission after treatment in specialized services. Current care as usual (CAU) for these
patients consists of long-term supportive contacts. Termination of CAU is often not considered to be an option due
to persistent symptoms, a low level of functioning, and the absence of further treatment options. A new
intervention, ZemCAD, offers a program focused on rehabilitation and self-management, followed by referral back
to primary care.
Methods: This multicenter randomized controlled trial was carried out in twelve specialized outpatient mental
health care services in the Netherlands. Consenting and eligible patients were invited for the MINI interview and
the baseline questionnaire. Assessments were done at 6 (T1), 12 (T2) and 18 (T3) months post baseline. We used
linear mixed model analysis (LMM) to ascertain the effectiveness of the ZemCAD group relative to the CAU group
on quality of life, symptom severity and empowerment.
Results: In total 141 patients were included. The results at 18-month follow-up regarding to quality of life and
symptom severity, showed no significant differences between the ZemCAD group and the CAU group, except on
the ‘social relationships’-domain (d = 0.37). With regard to empowerment a significant difference between both
groups was observed in the total empowerment score and one empowerment dimension (d = 0.45 and d = 0.39,
respectively). After the ZemCAD intervention, more patients went from specialized outpatient mental health
services back to a less specialized health care setting with less intensive treatment, such as primary care.
(Continued on next page)
* Correspondence: m.zoun@propersona.nl
1Behavioural Science Institute, Radboud University Medical Center, PO Box
9104, 6500, HE, Nijmegen, The Netherlands
2Pro Persona Mental Health Care, Wolfheze 2, 6874 BE, Wolfheze, The
Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zoun et al. BMC Psychiatry           (2019) 19:46 
https://doi.org/10.1186/s12888-019-2013-y
(Continued from previous page)
Conclusion: The findings in this study suggest that patients with chronic and treatment-resistant anxiety and
depression using the ZemCAD intervention improve on empowerment but not on symptom severity or quality of
life. Since little is known about the effects of rehabilitation and self-management in patients with chronic and
treatment resistant anxiety and depressive disorders, this is a first attempt to provide a proof-of-concept study in
this under-researched but important field.
Trial registration: Netherlands Trial Register: NTR3335, registered 7 March 2012.
Keywords: Anxiety, Depression, Chronic, Treatment resistant, Self-management, Randomized controlled trial,
Specialized outpatient mental health care, Primary care
Background
Anxiety and depressive disorders are common mental
disorders. Lifetime prevalence in the Netherlands, accor
ding to NEMESIS-2 (Netherlands Mental Health Survey
and Incidence Study-2), is 19.6% for anxiety disorders, and
18.7% for depressive disorders [1, 2], not much different
from other developed countries. In specialized outpatient
mental health services, anxiety and depressive disorders are
also common: 22.2% of outpatients have an anxiety dis-
order and 37.2% a depressive disorder [2]. Treatment for
these patients generally is provided in accordance with
(inter-)national multidisciplinary guidelines [3–5]. However,
a substantial part of these patients does not achieve symp-
tomatic remission after treatment in these specialized ser-
vices, resulting in so-called treatment resistance [6] and a
chronic course. The estimated chronicity for anxiety disor-
ders is 41.9, and 24.5% for depressive disorders [7]. Chronic
and treatment resistant anxiety and depressive disorders
are associated with more intense suffering, increased risk of
suicide, and decreased social functioning [8, 9].
Current care as usual (CAU) for patients with chronic
and treatment-resistant anxiety or depressive disorders in
many countries consists of long-term supportive contacts
with a community psychiatric nurse, combined with phar-
macological management by a psychiatrist. Termination of
CAU is often not considered to be an option due to persist-
ent symptoms, a low level of functioning, and the absence
of further treatment options. Data on the effectiveness on
this CAU is lacking [10]. In order to offer these patients a
different perspective, a psychosocial rehabilitation approach
focused on specific goals could be more suitable [11, 12].
However, research on the feasibility and effectiveness of re-
habilitation approaches for chronic and treatment resistant
anxiety and depressive disorders in specialized outpatient
mental health care is not available.
An increasingly important element in rehabilitation
programs, is a focus on self-management. In long-term
health problems, self-management is a method to focus
on enhancement of patients’ autonomy and responsibil-
ity and on the restoration of functioning – less on the
reduction of symptoms. Self-management refers to “the
training, skill acquisition, and interventions through
which patients who suffer from a disease or chronic con-
dition may take care of themselves and manage their
illnesses” [13]. Self-management is considered essential
in managing a chronic disease. We can differentiate
three levels of self-management: 1) the shift from a com-
pliant model to a participation model, where responsibil-
ities and management shifts from professional to
patient, 2) the ability to handle the chronic disease, and
3) self-management as intervention to train the patient
to handle a chronic disease properly [14]. Self-mana
gement leads to patients’ empowerment, and it may also
contribute to quality of life, which is known to be lower
in people with more symptoms [15–19]. Some research
is done into helpful self-management strategies to cope
with enduring depression from the patients’ point of
view [20–22], but, to our knowledge, little is known
about the effects of rehabilitation and self-management
on quality of life, symptom severity, and empowerment
in patients with chronic and treatment resistant anxiety
and depressive disorders.
In addition to self-management, empowerment as a
concept in mental health care has been receiving grow-
ing attention in the last years. The concept is defined in
many ways, but “a distinction can be made between em-
powerment at the individual and the collective level. At
the individual level, empowerment is about processes in
which the person rediscovers his identity and self-esteem
and takes his life in his own hands. At the collective
level, it is about the contribution by people with lived
experience to the organisation and practice of mental
health care and society” [23].
There are, to our knowledge, hardly any evidence-
based treatment interventions for patients with chronic
and treatment-resistant anxiety and depressive disorders.
Due to the transition of the Dutch health care system
where the aim is to refer chronic patients to less inten-
sive levels of care when possible, we need to make
cost-effective use of resources. Therefore a new inter-
vention is developed with focus on self-management
combined with the transition from specialized outpatient
mental health care to primary care. The new interven-
tion, ZemCAD (English: SemCAD; Self-management for
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Chronic Anxiety and Depression), was developed for pa-
tients with chronic and treatment resistant anxiety or
depressive disorders in specialized outpatient mental
health care. Treatment resistant patients in this study
have been described as patients who had received at
least one psychological treatment and at least three me
dication steps according to the national multidisciplinary
guidelines on anxiety and depressive disorders. The inter
vention is provided by a trained professional (usually a
community psychiatric nurse). In this randomized con-
trolled trial [24], the effects of the ZemCAD intervention
on quality of life, symptom severity, and empowerment
compared to CAU are evaluated.
We had two research questions. First, compared to
CAU, what is the effectiveness of the ZemCAD interven-
tion on quality of life, symptom severity and empower-
ment? Second, how successful was the referral of pa
tients included in the ZemCAD intervention from spe
cialized outpatient mental health services to less special-
ized health care settings, such as primary care?
Methods
Design and participants
This multicenter randomized controlled trial in two parallel
groups was carried out in twelve specialized outpatient men-
tal health care services in the Netherlands. These twelve ser-
vices offered outpatient treatment interventions in accor
dance with the (inter-)national multidisciplinary guidelines,
and prolonged treatment for patients with chronic and treat-
ment resistant anxiety or depressive disorders.
Participants had an anxiety or depressive disorder ac-
cording to the DSM-IV, were over 18 years old, received
treatment for at least two years in specialized outpatient
mental health care, had received at least one psycho-
logical treatment and at least three medication steps ac-
cording to the national multidisciplinary guidelines on
anxiety and depressive disorders [25]. They were regar
ded as treatment-resistant by their clinicians, meaning
that prolonged treatment in a specialized outpatient
mental health service according to the professional is
unlikely to improve clinical outcomes. They had sup-
portive contacts with a community psychiatric nurse. All
gave written informed consent to participate in the
study. Patients were excluded from participation if they
had a life-threatening medical condition, dementia,
psychotic or bipolar disorder, alcohol or drugs depend-
ence, had cognitive problems or indications for low IQ
or were not fluent in the Dutch language.
First we asked clinicians to select patients (on a
form) who could meet our inclusion criteria. Then we
checked the forms. If patients did not fully meet the
inclusion criteria, we consulted with the clinician. In
some cases we considered a patient who did not fully
meet the inclusion criteria suitable to participate. In
this case there was a lifetime diagnosis, a low level of
functioning, and persistent symptoms. All patients
that were eligible for participating in the ZemCAD
study were asked to participate by their clinician, who
informed the patient about the study and provided an
information letter to take home. If the patient was in-
terested and consented to participate, the signed in-
formed consent was sent to the coordinating research
centre. Then patients were invited for the Mini-Inter-
national Neuropsychiatric Interview (MINI interview)
to formally check if the current DSM-IV disorders
were present. The MINI is a semi-structured and
well-validated diagnostic interview to establish psychi-
atric disorders according to the DSM-IV [26]. The
MINI was administered at the mental health service
providing the treatment of the patient. After inclu
sion, patients received the baseline questionnaire.
After completing the baseline questionnaire, the pa-
tient was allocated to the ZemCAD group or the CAU
group, using a randomization schedule designed by an
independent statistician. To evenly distribute ZemCAD/
CAU across community psychiatric nurses, block rando
mization (block size of four) was used. After baseline
(T0) assessments were done at 6 (T1), 12 (T2) and 18
(T3) months post baseline. All participants in the Zem-
CAD group started the intervention after T0 (baseline).
The intervention has a duration of twenty-six weeks. So
T1 is a post-treatment assessment. T2 and T3 are fo
llow-up assessments. The questionnaires (except for the
MINI interview) were completed over the internet. If a
patient had no access to the internet, the questionnaires
were completed on paper.
In the intervention group (ZemCAD) treatment integ-
rity was assessed for each participating patient using a
checklist that the community psychiatric nurse completes
at the end of each treatment session. In this checklist the
nurse could indicate on which points the treatment differs
from the ZemCAD protocol. Patients who were allocated
to the CAU group often continued receiving care from
their current community psychiatric nurse. Since there is
no clear treatment guideline for CAU, treatment integrity
was not assessed in the control group.
Patients were informed that participation in the study
was voluntary and that they could withdraw from the
study at any time. The privacy of the participants was
guaranteed by anonymizing the data. This study has
been approved by the Institutional Review Board of the
University Medical Center Utrecht for all participating
sites (NL33674.097.10, registration number 10.218).
Intervention
The ZemCAD intervention is a treatment protocol for
patients with chronic and treatment-resistant anxiety or
depressive disorders, and directed at rehabilitation and
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self-management. It is based on an existing treatment
protocol for patients with chronic depression [27], adapted
for patients with chronic and treatment resistant anxiety or
depressive disorders [28]. The ZemCAD intervention was
carried out by 29 trained professionals (usually community
psychiatric nurses) in twelve participating specialized out-
patient mental health care services in the Netherlands, and
at the end followed by referral back to primary care.
Patients receiving the ZemCAD intervention were al-
located to a new and trained professional. This clearly
marked the transition from CAU to ZemCAD for both
patient and professional. The training of the participat-
ing professionals in the ZemCAD group consisted of a
two-day course. A prerequisite was that the professionals
study the intervention in advance. The two-day course
was provided by an expert and trainer in cognitive be-
havioral therapy and motivational skills for anxiety and
depressive disorders. The training combined self-study,
lectures, assignments, and group discussions. During the
study, three additional booster sessions were given. In
addition, in each mental health service monthly booster
sessions for the professionals were scheduled.
The intervention consists of thirteen sessions over
twenty-six weeks. First, patients and their families were
educated about the nature of their chronic disorder,
about suicidality and crises, and they learn how to cope
with these conditions and events. An action plan to
re-establish social contacts and improve daily living ac-
tivities are examples of parts of the intervention.
The ZemCAD intervention consists of three parts. The
first part is an introduction phase of three weeks with
weekly sessions. The goals for the professionals are to get
acquainted with the patient and family, and explain the
treatment. Patients make an individual treatment plan,
identify symptoms and daily activities, keep a log of symp-
toms, and learn how they can accept lifestyle changes due
to having a chronic disease. The second part is a coaching
and treatment phase of fourteen weeks with sessions every
second week. Patients start again engaging in social activ-
ities, they are stimulated to maintain a daily structure, and
learn to use general problem solving skills to cope with
their chronic disease. The third part is the final phase of
nine weeks with sessions every three weeks. Topics are to
make an action plan on how to deal with crisis situations
and to further practice with earlier mentioned skills. Fi-
nally, patients are referred to primary care. Every primary
care practice is asked to select a mental health profes-
sional who works in close collaboration with the general
practitioner and actively monitors functioning of the pa-
tient. After referral to primary care, the general practi-
tioner is responsible for the prescription of medication.
Both mental health professional in primary care and gen-
eral practitioner have easy access to specialized outpatient
mental health services for liaison consultation if required.
Control condition
Patients who were allocated to the CAU group continued
to receive specialized outpatient mental health care, which
usually consisted of long-term supportive contacts with a
community psychiatric nurse, and pharmacological man-
agement by a psychiatrist. Apart from that, some patients
had contacts with a psychologist or a nurse practitioner,
or just a psychiatrist. But in all cases it concerned support-
ive treatment. There was no other treatment at that time,
such as cognitive behavioural therapy. CAU may also in-
volve termination of treatment in specialized outpatient
mental health care and referral back to primary care. In
the ZemCAD intervention, however, this referral is
planned within the intervention and therefore anticipated,
while in the CAU group the referral and termination of
the treatment only occurs when indicated.
Measurements and outcomes
At baseline demographics, MINI diagnosis, quality of life,
symptom severity, and empowerment were measured.
Follow-up measurements were on quality of life, symptom
severity, and empowerment. These measurements took
place 6, 12, and 18months after baseline. Since referral
back to primary care is part of the ZemCAD intervention,
we conducted an additional questionnaire after finishing
the intervention. Among other questions, we asked pa-
tients where they currently received treatment (specialized
outpatient mental health care or primary care).
Quality of life (main outcome)
Quality of life was measured with the World Health
Organization Quality of Life instrument, Brief version
(WHOQOL-BREF) [29, 30]. The WHOQOL-BREF is a
26-item version of the WHOQOL-100 assessment. It pro-
duces a quality of life profile with four domain scores with
good established psychometric properties: physical health
(Cronbach’s α = 0.82), psychological health (Cronbach’s α
= 0.81), social relationships (Cronbach’s α = 0.68), and en-
vironment (Cronbach’s α = 0.80) [29, 30]. The scores on
the WHOQOL-BREF are scaled in a positive direction (i.e.
higher scores mean higher quality of life).
Anxiety severity
Anxiety severity was measured with the Beck Anxiety
Inventory (BAI), with good established psychometric
properties (Cronbach’s α = 0.92) [31]. It is a validated
self-rated questionnaire to assess the severity of anxiety
symptoms. The inventory consists of 21 items. The
scores on the BAI are scaled in a negative direction (i.e.
lower scores mean less symptom severity).
Depression severity
Depression severity was measured with the Patient
Health Questionnaire-9 (PHQ-9), a validated self-rated
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questionnaire to assess the severity of depression symp-
toms with good established psychometric properties
(Cronbach’s α = 0.86–0.89) [32, 33]. It includes the 9
symptoms of the DSM-IV depressive episode. A higher
PHQ score means higher severity.
Empowerment
Empowerment is assessed using the Netherlands Em-
powerment List (NEL), with good established psychomet-
ric properties (Cronbach’s α = 0.94) [23, 34]. It is a 40-item
self-report questionnaire to assess empowerment. Respon-
dents indicate the extent to which they agree or disagree
with the statements on a five-point scale. The NEL
produces an overall empowerment score, and in addition
it is possible to derive six dimension scores: professional
help, social support, confidence and purpose, connected-
ness, self-management, and caring community. The scores
on the NEL are scaled in a positive direction (i.e. higher
scores mean more empowerment).
Analyses
Descriptive statistics were used for presenting the demo-
graphics of the sample. All outcome analyses were con-
ducted in agreement with the intention-to-treat (ITT)
principle, as required by the CONSORT statement [35].
The estimated marginal means were calculated to see the
mean response for each outcome variable over time. We
used linear mixed model analysis (LMM) to ascertain the
relative effectiveness of the ZemCAD group relative to the
CAU group on the WHOQOL-BREF, BAI, PHQ-9, and
NEL. If differences in baseline data were present, we ad-
justed for relevant baseline characteristics, by including
baseline variables as covariates in the model. The linear
mixed models were carried out in two steps. First we en-
tered the treatment variable (ZemCAD vs CAU) and the
covariates for which adjustments were needed into the
model as fixed effects. As random effects, we entered the
subject_ID variable into the model. The covariance struc-
ture was ‘unstructured’, and the method was ‘residual
maximum likelihood’ (reml), which offers better estimates
in smaller samples. When the main effect of the condition
was statistically significant, we carried out the second step
to see how effects developed over time. To that end, we
also modelled interactions of the treatment with time. The
results were considered significant at p < 0.05. The stan-
dardized difference between two groups, Cohen’s d, was
computed from the value of the t-test of the differences
between the two groups: d = 2 t / √(df) [36]. In the
equation ‘df ’ is the degrees of freedom for the t-test. All
analyses were conducted in SPSS 22 and Stata 14.2.
Recruitment and patient characteristics
In total 268 patients were signed up by their mental
health care professional to participate in the ZemCAD
study, of whom 141 patients were included. 70 patients
were allocated to the ZemCAD group, 71 patients were
allocated to the CAU group. Almost all of the 127 exclu-
sions were because of the patient’s unwillingness to par-
ticipate in the research (124). Two patients were
excluded because of a psychotic or bipolar disorder. The
patient flow through the trial is depicted in Fig. 1.
Results
Baseline characteristics
Mean age of the study sample was 47.5 ± 8.3 years, 66.0%
was female. According to the MINI interview, 17.0% had
an anxiety disorder, 26.2% a depressive disorder, 44.0%
had both a depressive and an anxiety disorder, and 12.8%
had no current disorder. The mean age at which patients
first experienced anxiety or depressive symptoms was
26.6 ± 13.19 years. At baseline, clinically relevant differ-
ences were found between the ZemCAD and CAU groups
on ‘partner status’ and ‘duration of current symptoms’.
There were more singles in the CAU group and also pa-
tients had the longest duration of current symptoms in
the CAU group. The mean duration of current symptoms
was 4.79 ± 7.14 years. There were no clinically relevant dif-
ferences found on quality of life, symptom severity, and
empowerment. The BAI scores are classified as minimal
anxiety (0 to 9), mild anxiety (10 to 16), moderate anxiety
(17 to 29), and severe anxiety (30 to 63). The PHQ-9
scores are classified as minimal depression (0 to 4), mild
depression (5 to 9), moderate depression (10 to 14), mod-
erately severe depression (15 to 19), and severe depression
(20 to 27). If we look at the average score on the BAI and
PHQ-9 measurements in our sample, we could describe
the participants as severely ill. An overview of baseline
characteristics is provided in Table 1.
Effectiveness of the ZemCAD intervention
An overview of linear mixed model analyses on quality
of life, anxiety and depressive symptom severity, and em-
powerment is presented in Table 2 where unadjusted
and baseline adjusted effects are presented as the be-
tween-group difference in the mean change over all
follow-ups simultaneously. The results of these analyses
showed that quality of life, measured with the WH
OQOL-BREF was not significantly different between
both conditions, except on the ‘social relationships’-
domain in favour of the ZemCAD intervention (P =
0.041), with a medium effect size (d = 0.37) in the baseline
adjusted analysis. Symptom severity, measured with the
BAI and PHQ-9, was not statistically different. Empower-
ment, measured with the NEL, showed a significant differ-
ence between conditions in favour of the ZemCAD
intervention (P = 0.013) with a medium effect size (d =
0.45). When looking at the distinct empowerment dimen-
sions a significant difference is observed between the
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conditions in favour of the ZemCAD intervention in the
‘caring community’-dimension (P = 0.030), with a medium
effect size (d = 0.39). In the ‘confidence and purpose’-di-
mension we found a significant difference (P = 0.035) in
the unadjusted model and a trend towards significance (P
= 0.056) in the adjusted model in favour of the ZemCAD
intervention.
How effects developed over time
In addition to the estimated differences in mean change of
outcomes between baseline and 18-month follow-up for
the intervention group versus the control group (overall
intervention effect), we also looked at how effects devel-
oped over time. An overview of the estimated marginal
means (adjusted for ‘partner status’ and ‘duration of
current symptoms’) for all outcomes at baseline, and 6, 12
and 18-month follow-up are presented in Appendix 1. In
symptom severity we found no significant differences be-
tween conditions. In quality of life, we found a significant
difference at 12-month follow-up in favour of the
ZemCAD group (P = 0.025). Also in empowerment we
found significant differences at 6-month (P = 0.034) and
Fig. 1 Flowchart of participants
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12-month (P = 0.016) follow-up, both in favour of the
ZemCAD group. In both quality of life and empowerment
the significant effects do not remain at 18-month
follow-up. Because few significant differences were found
in the overall intervention effect, we only show the total
scores of the questionnaires. An overview on how effects
developed over time is provided in Table 3. For more de-
tails on how the effects developed over time, including the
domains of the WHOQOL-BREF and the dimensions of
the NEL, see Appendix 2.
Change of care setting
After finishing the ZemCAD intervention, we asked pa-
tients where they currently received treatment (special-
ized outpatient mental health care or less specialized
mental health care, such as primary care). The response
was 70.9% (n = 100). In the ZemCAD group 44.0% of pa-
tients, and in the CAU group 62.0%, was still receiving
treatment in specialized outpatient mental health care
(P = 0.071). As regards to treatment in primary care,
36.7% of patients in the ZemCAD group, and 28.6% in
the CAU group, was receiving treatment there (P =
0.389). Then 77.8% of patients in the ZemCAD group,
and 66.7% of patients in the CAU group perceived the
treatment in primary care as ‘good’ (P = 0.495).
Treatment integrity
Treatment integrity could be assessed in 60 patients in
the ZemCAD group (out of 70) using a checklist that
the trained professional completed at the end of each
treatment session. In total 19 (41.4%) of the patients did
not finish all sessions of the ZemCAD intervention. The
treatment integrity ‘response and proper protocol execu-
tion’ is provided in Table 4.
Discussion
Main findings
This trial evaluated the effectiveness of a rehabilita-
tion and self-management training for patients with
chronic and treatment resistant anxiety and depressive
disorders on quality of life, symptom severity, and
empowerment. The results at 18-month follow-up re-
garding our primary outcome, quality of life measured
with the WHOQOL-BREF, showed no significant dif-
ferences between the experimental treatment and care
as usual, except on the ‘social relationships’-domain
(P = 0.041), with a moderate standardized effect size
(d = 0.37) in favour of the ZemCAD group. There
were no significant differences for anxiety symptom
severity (BAI) and depressive symptom severity
(PHQ-9) either. With regard to empowerment a sig-
nificant difference between both groups was observed
in the total empowerment (NEL) score and one em-
powerment dimension (caring community) of medium
sizes (d = 0.45 and d = 0.39, respectively), both in
favour of the ZemCAD group. Treatment integrity was
assessed with a checklist that the trained professionals
(mostly community psychiatric nurses) completed at the
end of each treatment session. In total 19 (41.4%) of the
patients did not finish all sessions of the ZemCAD inter-
vention. After the ZemCAD intervention, more patients
went from specialized outpatient mental health services
back to a less specialized health care setting with less
intensive treatment, such as primary care.
Table 1 Baseline characteristics of the participants in the
intervention (ZemCAD) and control (CAU) groups (n = 141)
ZemCAD
(n = 70)
Control
(n = 71)
Gender, n (%)
Female 46 (65.70) 47 (66.20)
Male 24 (34.30) 24 (33.80)
Age (years)
Mean (SD) 47.03 (7.68) 47.87 (8.90)
Range 28–63 27–63
Education, n (%)
Low 34 (50.00) 38 (53.50)
Intermediate 12 (17.60) 16 (22.50)
High 22 (32.40) 17 (23.90)
Employment, n (%)
Paid 14 (20.60) 13 (18.30)
No paid 54 (79.40) 58 (81.70)
Nationality, n (%)
Dutch 59 (84.30) 59 (83.10)
Other 11 (15.70) 12 (16.90)
Partner status, n (%)
Single 26 (37.10) 39 (54.90)
Living with partner 44 (62.90) 32 (45.10)
Age of first onset, M (SD) 27.57 (12.22) 24.97 (14.07)
Duration of current symptoms (years), M (SD) 3.59 (5.90) 5.99 (8.06)
Diagnosis according to MINIa, n (%)
Anxiety 12 (17.10) 12 (16.90)
Depression 16 (22.90) 21 (29.60)
Both anxiety and depression 29 (41.40) 33 (46.50)
No current anxiety or depression 13 (18.60) 5 (7.00)
Quality of life (WHOQOL-BREFb), M (SD) 73.49 (15.34) 72.03 (13.11)
Anxiety (BAIc), M (SD) 43.82 (13.57) 45.28 (11.27)
Depression (PHQ-9d), M (SD) 22.51 (6.42) 23.18 (6.58)
Empowerment (NELe), M (SD) 121.88 (20.46) 121.48 (16.57)
aMINI = MINI International Neuropsychiatric Interview
bWHOQOL-BREF World Health Organisation Quality of Life, Brief version
cBAI Beck Anxiety Inventory
dPHQ-9 Patient Health Questionnaire
eNEL Netherlands Empowerment List
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Comparison with other studies
Only a few studies in this particular patient group are
available for comparison. There are several self-mana
gement programs for patients with chronic psychiatric
conditions that produce positive changes in health out-
comes by teaching skills to better manage symptoms,
enhance quality of life, and maintain higher levels of
health and functioning. We found three of such pro
grams, which are the Illness Management and Recovery
(IMR) program, the Wellness Recovery Action Planning
(WRAP), and the ‘Organized Self-Management Support
Services’ all for patients with a broad range of mental
disorders. In these programs positive effects were found
on various outcomes. In comparison to previous studies
that evaluated self-management programs in (chronic)
psychiatric conditions in general, the current study was
Table 2 Estimated differences in mean change of outcomes (unadjusted and adjusted)a between baseline and 18-month follow-up
for the intervention group (ZemCAD) versus the control group (CAU)
Outcome Estimate of mean difference (95% CI) t (df ) P Cohen’s db
Quality of life (WHOQOL-BREFc)
Total score unadjusted model 2.40 (− 0.23 to 5.03) 1.81 (128) 0.073 0.31
adjusted model 2.42 (− 0.27 to 5.11) 1.78 (129) 0.077
Domain 1; unadjusted model 0.95 (− 0.06 to 1.95) 1.87 (127) 0.064 0.29
Physical health adjusted model 0.86 (−0.17 to 1.89) 1.65 (127) 0.101
Domain 2; unadjusted model 0.68 (− 0.07 to 1.42) 1.78 (126) 0.077 0.32
Psychological adjusted model 0.71 (− 0.07 to 1.48) 1.81 (125) 0.074
Domain 3; unadjusted model 0.39 (− 0.03 to 0.81) 1.82 (122) 0.072 0.3
Social relationships adjusted model 0.46 (0.02 to 0.89) 2.07 (122) 0.041*
Domain 4; unadjusted model 0.20 (− 0.85 to 1.25) 0.38 (129) 0.704 0.07
Environment adjusted model 0.22 (− 0.84 to 1.28) 0.41 (129) 0.685
Anxiety (BAId)
Total score unadjusted model −0.56 (− 3.11 to 1.99) −0.44 (117) 0.663 −0.07
adjusted model −0.53 (− 3.17 to 2.11) −0.40 (117) 0.693
Depression (PHQ-9e)
Total score unadjusted model 0.06 (− 1.46 to 1.58) 0.08 (126) 0.936 0.01
adjusted model 0.06 (− 1.51 to 1.63) 0.08 (125) 0.940
Empowerment (NELf)
Total score unadjusted model 5.00 (1.20 to 8.80) 2.60 (127) 0.010* 0.45
adjusted model 5.00 (1.09 to 8.92) 2.53 (126) 0.013*
Dimension 1; unadjusted model 0.64 (− 0.47 to 1.76) 1.14 (129) 0.255 0.24
Professional help adjusted model 0.76 (−0.38 to 1.90) 1.33 (128) 0.187
Dimension 2; unadjusted model 0.80 (−0.29 to 1.90) 1.46 (125) 0.148 0.20
Social support adjusted model 0.61 (−0.50 to 1.73) 1.09 (124) 0.278
Dimension 3; unadjusted model 1.78 (0.13 to 3.42) 2.13 (126) 0.035* 0.35
Confidence and purpose adjusted model 1.65 (− 0.04 to 3.35) 1.93 (124) 0.056
Dimension 4; unadjusted model 0.80 (− 0.14 to 1.74) 1.68 (128) 0.096 0.27
Connectedness adjusted model 0.75 (− 0.21 to 1.72) 1.54 (128) 0.125
Dimension 5; unadjusted model 0.30 (− 0.38 to 0.99) 0.88 (127) 0.380 0.15
Self-management adjusted model 0.30 (− 0.40 to 1.01) 0.85 (127) 0.396
Dimension 6; unadjusted model 0.86 (0.05 to 1.68) 2.09 (123) 0.038* 0.39
Caring community adjusted model 0.93 (0.09 to 1.77) 2.19 (123) 0.030*
*Significant difference
aUnadjusted model: crude association. Adjusted model: adjusted for ‘partner status’ and ‘duration of current symptoms’
bd = 2 t / √(df)
cWHOQOL-BREF World Health Organisation Quality of Life, Brief version
dBAI Beck Anxiety Inventory
ePHQ-9 Patient Health Questionnaire
fNEL Netherlands Empowerment List
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aimed specifically at patients with chronic and treatment
resistant anxiety and depressive disorders. Hasson-Oha-
yon et al. [37] included patients with severe mental ill-
ness in general who received a more intensive treatment,
while Cook et al. [38] focused on patients with anxiety
and depression, but not a treatment resistant sample.
The follow-up period was longer in the ZemCAD inter-
vention. Ludman et al. [39] focused on patients with
chronic depression, but had a longer, more intensive treat-
ment than the ZemCAD intervention. All three studies
had group settings and a peer support component was
present. There was a focus on (symptomatic) recovery in
all three studies as well contrary to our research, where
the aim was on quality of life and empowerment.
Findings in context
Given the long-term nature of anxiety and depressive
symptoms in this group (the mean duration of current
symptoms was 4.79 ± 7.14 years), we did not expect im-
mediate symptomatic improvement. However, we did
measure symptom severity to make sure that patients
would not deteriorate, and found that patients using the
ZemCAD intervention remained at least stable despite
the fact that they knew that treatment in specialized
mental health care would stop when they completed the
ZemCAD intervention. Positive effects were expected in
both quality of life and empowerment, and mainly found
in the latter. Also on the ‘social relationships’-domain of
the quality of life questionnaire a significant effect was
found. The effects may have been too small to have had
a substantial impact on quality of life, which is known to
be a composite measure of satisfaction with personal
functioning, self-esteem and many other things. Perhaps
the way forward for patients with chronic and treatment
resistant anxiety and depressive disorders is to accept
the chronic nature of their disorder, and learn to develop
effective self-management strategies [40] to enhance a
shift from symptomatic remission towards improved
personal and social functioning. It is unclear which in-
terventions promote empowerment, but it is an assump-
tion that self-management plays a major role [41]. Our
study population had severe and chronic anxiety and de-
pressive symptoms. They had a low quality of life, with
scores below the average of the general population in
the psychological and social domain [29]. Also there is a
large number of low-educated patients (around 50%),
and we know that in that case the possibilities for
change are small [10]. The fact that there is a significant
increase in empowerment in these patients is therefore
promising. Whether the ZemCAD intervention offered
the right approach to improve self-management and per-
sonal and social functioning, is questionable. With re-
gard to the treatment integrity, we found that 19 (41.4%)
of the patients did not finish all sessions of the ZemCAD
intervention. This raises the question whether a higher
compliance could lead to more positive effects on the
Table 3 Estimated differencesa in change of outcome in the intervention group over follow-ups at 6, 12 and 18 months
Outcome Estimate of mean difference (95% CI) t (df ) P
Quality of life (WHOQOL-BREFb)
Total score 6 months (T1) 0.69 (− 2.56 to 3.93) 0.42 (354) 0.678
12 months (T2) 3.88 (0.49 to 7.27) 2.25 (356) 0.025*
18 months (T3) 1.89 (− 1.53 to 5.31) 1.09 (356) 0.279
Anxiety (BAIc)
Total score 6 months (T1) 0.88 (− 2.37 to 4.12) 0.53 (352) 0.595
12 months (T2) −1.31 (− 4.72 to 2.10) −0.76 (355) 0.451
18 months (T3) −0.27 (− 3.70 to 3.16) −0.16 (355) 0.875
Depression (PHQ-9d)
Total score 6 months (T1) 0.09 (− 1.74 to 1.92) 0.10 (354) 0.921
12 months (T2) 0.09 (−1.82 to 2.01) 0.10 (358) 0.923
18 months (T3) 1.14 (− 0.79 to 3.08) 1.16 (358) 0.247
Empowerment (NELe)
Total score 6 months (T1) 5.41 (0.42 to 10.40) 2.13 (353) 0.034*
12 months (T2) 6.39 (1.19 to 11.59) 2.42 (355) 0.016*
18 months (T3) 0.00 (− 5.24 to 5.25) 0.00 (355) 0.999
*Significant difference (of the ‘treatment × time’ effect relative to the control condition at baseline)
aAll estimates are adjusted for ‘partner status’ and ‘duration of current symptoms’
bWHOQOL-BREF World Health Organisation Quality of Life, Brief version
cBAI Beck Anxiety Inventory
dPHQ-9 Patient Health Questionnaire
eNEL Netherlands Empowerment List
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Table 4 Treatment integrity; response and proper protocol execution
Sessions Response % (n) Proper protocol execution % (n)
Session 1 85.7 (60)
a: treatment and research discussed? 98.3 (59)
b: explanation about the intervention? 98.3 (59)
c: symptom severity established? 51.7 (31)
d: treatment agreement prepared? 74.6 (44)
e: appointment series made? 63.3 (38)
Session 2 81.4 (57)
a: explanation about exposure and helplessness? 91.2 (52)
b: motivation to change discussed? 98.2 (56)
c: registration daily structure discussed? 94.7 (54)
Session 3 74.3 (52)
a: instructions registration activities, anxiety, depression discussed? 96.2 (50)
b: partner/close relative invited? 78.8 (41)
Session 4 74.3 (52)
a: consequence of symptoms on daily life discussed? 92.3 (48)
Session 5 71.4 (50)
a: problem analysis made? 78.0 (39)
b: treatment goals specified? 84.0 (42)
Session 6 71.4 (50)
a: explanation about attribution? 82.0 (41)
Session 7 65.7 (46)
a: plan of activation made? 89.1 (41)
Session 8 62.9 (44)
a: relapse prevention plan made? 75.0 (33)
Session 9 58.6 (41)
a: crisis/signalling plan made? 82.9 (34)
Session10 58.6 (41)
a: sleep-wake rhythm discussed? 92.7 (38)
Session 11 58.6 (41)
a: dismissal date discussed? 90.2 (37)
b: desired care after intervention discussed? 85.4 (35)
c: contact with general practitioner? 46.3 (19)
Session 12 58.6 (41)
a: symptom severity established? 68.3 (28)
b: appointments with other caregivers made? 58.5 (24)
Session 13 58.6 (41)
a: final report made? 75.6 (31)
b: treatment completed? 80.5 (33)
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outcome measurements of the ZemCAD intervention.
Ending treatment in specialized mental health services
was part of the ZemCAD intervention. This has not
been successful in all cases, 44.0% was still receiving
treatment in specialized outpatient mental health care,
due to the high level of symptoms. This can also be re-
lated to compliance to the ZemCAD intervention.
Strengths and limitations
This trial was conducted in a complex group of patients
with chronic and treatment resistant anxiety or depres-
sive disorders. We were able to include patients from
various specialized mental health services in the
Netherlands. Most patients maintained in the trial and
completed the last measurements (78,8%). Despite the
fact that patients were told in advance that treatment in
specialized mental health services would stop after com-
pleting the ZemCAD intervention, we were able to in-
clude 141 patients with severe mental health problems.
There were a number of limitations to this study. First,
we used broad eligibility criteria. The inclusion criteria
were based on the multidisciplinary guidelines and were
defined in consultation with experts. To avoid being too
restrictive and denying patients who might benefit from
the intervention access to ZemCAD, we included pa-
tients that according to the MINI interview did not have
an actual diagnosis, but were according to their health
care provider eligible due to a high level of symptoms
and a lifetime diagnosis. Furthermore it was possible to
include patients that, for example, did not want to take a
specific medication step like lithium addition. Not all pa-
tients in our study had therefore gone through the entire
multidisciplinary guideline for the treatment of depres-
sion or anxiety. Although a disadvantage of this ap-
proach is that a fairly heterogeneous group of patients
has been included, on the other hand this approach fits
well with current practice, where it is not always possible
to treat patients completely in accordance with the
multidisciplinary guidelines. Second, we did not describe
(co-morbid) personality disorders or social problems.
These factors may also contribute to the chronicity of
anxiety and depressive disorders. Third, the study relied
on the participants’ self-reported data that were uncor-
roborated by clinicians or independent assessors. This
may be a limitation, but provides information from the
patients’ perspective instead of a clinical judgement. We
know that clinicians are likely to be more positive when
it comes to recovery progress. Fourth, although this
study was not aiming to reduce symptoms, there was a
lack of symptom measures. In addition to the partici-
pants’ self-reported symptom severity data (BAI and
PHQ-9) we could have added, for example, the Hamilton
Depression Rating Scale (HAM-D) and the Hospital
Anxiety and Depression Scale – Anxiety subscale
(HADS-A) for anxiety and depression symptom severity
for more depth. Fifth, a significant proportion (47%) of
the patients who were eligible to participate in the Zem-
CAD study did not want to participate. Patients men-
tioned several reasons. It is possible that those who were
not included had more serious or chronic symptoms
than the group that did participate.
Conclusions
This trial on the effectiveness of a rehabilitation and
self-management training for patients with chronic and
treatment resistant anxiety and depressive disorders
showed little effectiveness on a couple of measures be-
tween the experimental treatment and care as usual. How-
ever, patients remained at least stable, and in the
ZemCAD group more patients (56% in the ZemCAD
group against 38% in the CAU group) could be referred to
less specialized mental health services, such as primary
care. Since little is known about the effects of rehabilita-
tion and self-management in patients with chronic and
treatment resistant anxiety and depressive disorders on
quality of life, symptom severity, and empowerment, this
is a first attempt to provide a proof-of-concept study in
this under-researched but important field.
Directions for further research
The ZemCAD intervention did not aim at symptom re-
duction. Perhaps this group of patients with chronic and
treatment resistant anxiety or depressive disorders needs
more focus on symptom reduction, combined with
self-management, to experience a higher quality of life. If
we look at how effects developed over time (Table 3 and
Appendix 2), we found significant differences in several
outcomes in quality of life and empowerment, on the
6-month and 12-month follow-up measurement. When
these effects occurred, they did not persist until the
18-month follow-up measurement. This could indicate
that perhaps timely booster-sessions are required to sus-
tain the positive effects in quality of life and empower-
ment. Further development of the ZemCAD intervention
could involve a group program and the use of peer sup-
port. Groups enable patients to better withstand alien-
ation and crisis because of the connectedness and social
support [42]. Peer support is proven to be supplementary
in various self-management programs [38, 39, 43]. Inter-
actions with peers may enhance patients’ belief in their
own ability to self-manage their lives, thus increasing
perceptions of recovery and lowering feelings of anxiety
and depression. It would be interesting to know what
self-management strategies patients use to cope with a
chronic and treatment resistant anxiety or depressive dis-
order, from the patients’ perspective. And it is relevant to
look at the health gains of the ZemCAD intervention,
from an economic point of view, relative to usual care.
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Appendix 1
Table 5 Estimated marginal means (EMM) of the outcomes
Outcome ZemCAD (n = 70) Control (n = 71)
EMM (SEMa) EMM (SEM)
Quality of life (WHOQOL-BREFb)
Total score Baseline 73.31 (1.73) 72.38 (1.75)
6 months (T1) 74.89 (1.74) 73.27 (1.79)
12 months (T2) 78.21 (1.78) 73.39 (1.82)
18 months (T3) 77.36 (1.79) 74.54 (1.82)
Domain 1; Baseline 18.13 (0.57) 17.86 (0.58)
Physical health 6 months (T1) 18.79 (0.58) 18.11 (0.60)
12 months (T2) 20.40 (0.60) 18.30 (0.61)
18 months (T3) 20.02 (0.61) 19.07 (0.61)
Domain 2; Baseline 15.31 (0.43) 15.40 (0.43)
Psychological 6 months (T1) 15.80 (0.43) 15.41 (0.45)
12 months (T2) 16.37 (0.45) 15.60 (0.46)
18 months (T3) 16.34 (0.45) 15.62 (0.46)
Domain 3; Baseline 8.23 (0.29) 8.62 (0.29)
Social relationships 6 months (T1) 8.55 (0.29) 8.77 (0.30)
12 months (T2) 8.70 (0.30) 8.36 (0.31)
18 months (T3) 8.66 (0.31) 8.60 (0.31)
Domain 4; Baseline 26.56 (0.61) 25.60 (0.61)
Environment 6 months (T1) 26.67 (0.61) 26.09 (0.63)
12 months (T2) 27.39 (0.63) 26.45 (0.64)
18 months (T3) 27.15 (0.63) 26.21 (0.64)
Anxiety (BAIc)
Total score Baseline 43.76 (1.50) 45.42 (1.52)
6 months (T1) 43.88 (1.52) 44.66 (1.56)
12 months (T2) 40.88 (1.56) 43.84 (1.61)
18 months (T3) 42.53 (1.58) 44.46 (1.60)
Depression (PHQ-9d)
Total score Baseline 22.46 (0.77) 23.33 (0.78)
6 months (T1) 21.16 (0.78) 21.93 (0.80)
12 months (T2) 19.86 (0.80) 20.63 (0.83)
18 months (T3) 21.27 (0.82) 20.99 (0.83)
Empowerment (NELe)
Total score Baseline 121.94 (2.35) 121.37 (2.38)
6 months (T1) 125.58 (2.38) 119.59 (2.45)
12 months (T2) 126.88 (2.44) 119.92 (2.50)
18 months (T3) 123.66 (2.47) 123.08 (2.50)
Dimension 1; Baseline 13.40 (0.57) 13.80 (0.58)
Professional help 6 months (T1) 13.65 (0.59) 12.78 (0.61)
12 months (T2) 12.28 (0.62) 12.16 (0.63)
18 months (T3) 9.39 (0.63) 12.23 (0.63)
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Table 5 Estimated marginal means (EMM) of the outcomes (Continued)
Outcome ZemCAD (n = 70) Control (n = 71)
EMM (SEMa) EMM (SEM)
Dimension 2; Baseline 23.03 (0.58) 23.78 (0.59)
Social support 6 months (T1) 23.55 (0.59) 23.52 (0.61)
12 months (T2) 24.10 (0.61) 23.77 (0.62)
18 months (T3) 23.99 (0.61) 23.47 (0.62)
Dimension 3; Baseline 34.98 (0.93) 34.29 (0.94)
Confidence and purpose 6 months (T1) 36.77 (0.94) 34.20 (0.96)
12 months (T2) 37.63 (0.96) 34.86 (0.99)
18 months (T3) 37.68 (0.97) 36.19 (0.99)
Dimension 4; Baseline 18.65 (0.46) 18.20 (0.47)
Connectedness 6 months (T1) 19.41 (0.47) 17.77 (0.48)
12 months (T2) 19.42 (0.49) 18.26 (0.50)
18 months (T3) 19.27 (0.49) 18.94 (0.50)
Dimension 5; Baseline 15.22 (0.37) 15.53 (0.38)
Self-management 6 months (T1) 15.48 (0.38) 15.72 (0.39)
12 months (T2) 16.15 (0.39) 15.48 (0.40)
18 months (T3) 16.20 (0.40) 16.03 (0.40)
Dimension 6; Baseline 16.66 (0.47) 15.79 (0.47)
Caring community 6 months (T1) 16.84 (0.48) 15.67 (0.49)
12 months (T2) 17.51 (0.49) 15.45 (0.50)
18 months (T3) 17.29 (0.50) 16.27 (0.50)
aSEM Standard error of the mean
bWHOQOL-BREF World Health Organisation Quality of Life, Brief version
cBAI Beck Anxiety Inventory
dPHQ-9 Patient Health Questionnaire
eNEL Netherlands Empowerment List
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Appendix 2
Table 6 Estimated differencesa in mean change at 6, 12 and 18 months
Outcome Estimate of mean difference (95% CI) t (df ) P
Quality of life (WHOQOL-BREFb)
Total score 6 months (T1) 0.69 (− 2.56 to 3.93) 0.42 (354) 0.678
12 months (T2) 3.88 (0.49 to 7.27) 2.25 (356) 0.025*
18 months (T3) 1.89 (− 1.53 to 5.31) 1.09 (356) 0.279
Domain 1; 6 months (T1) 0.41 (− 0.94 to 1.76) 0.60 (357) 0.549
Physical health 12 months (T2) 1.82 (0.42 to 3.23) 2.55 (361) 0.011*
18 months (T3) 0.68 (− 0.74 to 2.10) 0.95 (361) 0.345
Domain 2; 6 months (T1) 0.48 (− 0.43 to 1.40) 1.04 (354) 0.300
Psychological 12 months (T2) 0.87 (− 0.08 to 1.83) 1.79 (357) 0.074
18 months (T3) 0.82 (− 0.15 to 1.78) 1.66 (357) 0.098
Domain 3; 6 months (T1) 0.17 (− 0.46 to 0.79) 0.52 (353) 0.603
Social relationships 12 months (T2) 0.72 (0.07 to 1.37) 2.18 (356) 0.030*
18 months (T3) 0.44 (− 0.21 to 1.10) 1.33 (356) 0.186
Domain 4; 6 months (T1) −0.37 (− 1.61 to 0.87) −0.59 (355) 0.556
Environment 12 months (T2) −0.01 (− 1.30 to 1.29) −0.01 (357) 0.993
18 months (T3) −0.01 (− 1.32 to 1.30) −0.02 (357) 0.986
Anxiety (BAIc)
Total score 6 months (T1) 0.88 (− 2.37 to 4.12) 0.53 (352) 0.595
12 months (T2) −1.31 (− 4.72 to 2.10) −0.76 (355) 0.451
18 months (T3) −0.27 (− 3.70 to 3.16) −0.16 (355) 0.875
Depression (PHQ-9d)
Total score 6 months (T1) 0.09 (− 1.74 to 1.92) 0.10 (354) 0.921
12 months (T2) 0.09 (−1.82 to 2.01) 0.10 (358) 0.923
18 months (T3) 1.14 (− 0.79 to 3.08) 1.16 (358) 0.247
Empowerment (NELe)
Total score 6 months (T1) 5.41 (0.42 to 10.40) 2.13 (353) 0.034*
12 months (T2) 6.39 (1.19 to 11.59) 2.42 (355) 0.016*
18 months (T3) 0.00 (− 5.24 to 5.25) 0.00 (355) 0.999
Dimension 1; 6 months (T1) 1.26 (− 0.55 to 3.08) 1.37 (354) 0.172
Professional help 12 months (T2) 0.52 (−1.37 to 2.40) 0.54 (360) 0.590
18 months (T3) −2.45 (− 4.35 to − 0.55) −2.53 (361) 0.012*
Dimension 2; 6 months (T1) 0.78 (− 0.54 to 2.09) 1.16 (353) 0.245
Social support 12 months (T2) 1.07 (− 0.30 to 2.43) 1.54 (356) 0.125
18 months (T3) 1.27 (− 0.11 to 2.65) 1.82 (356) 0.070
Dimension 3; 6 months (T1) 1.88 (− 0.12 to 3.88) 1.84 (354) 0.066
Confidence and purpose 12 months (T2) 2.08 (− 0.01 to 4.16) 1.96 (356) 0.051
18 months (T3) 0.80 (−1.30 to 2.91) 0.75 (356) 0.452
Dimension 4; 6 months (T1) 1.19 (0.08 to 2.31) 2.11 (355) 0.036*
Connectedness 12 months (T2) 0.71 (− 0.44 to 1.87) 1.21 (358) 0.226
18 months (T3) −0.11 (− 1.28 to 1.06) −0.18 (358) 0.857
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